The new enforcement wave targeted high-visibility placements. Hims & Hers drew scrutiny over a Super Bowl advertisement promoting compounded weight-loss drugs without adequate risk disclosure.¹³ Eli Lilly and Novo Nordisk received warnings related to promotional communications judged to minimize or omit serious side effects.¹⁴ These were not obscure cable spots. They were mainstream cultural events.
Regulators are not banning ads. They are trying to close gaps that allow benefit-forward narratives to float above proportional risk context.
Yet the deeper question remains unresolved.
If the defense of high American drug prices is that we subsidize global innovation, why does that innovation require mass persuasion?
Part of the answer lies on the other end of the spectrum—the miracles.
In 2019, researchers published in the New England Journal of Medicine the case of a child with Batten disease who received a customized antisense therapy—milasen—designed specifically for her genetic mutation.¹⁵ It was a triumph of precision medicine. It was also a glimpse of a future where treatments are engineered for individuals.
Boston Children’s Hospital has described the research costs for such individualized programs as averaging roughly $1.6 million per case—astonishingly low by pharmaceutical standards, yet still reliant on extraordinary coordination and philanthropic support.¹⁶
The contrast is jarring.
On one side: bespoke cures built in months for a single child.
On the other: primetime commercials for six-figure therapies aimed at viewers who may not know they’re candidates.
Both exist in the same system.
And that system prices not at cost, but at leverage.
Insurance insulates patients from immediate sticker shock. Premiums absorb the difference. The signal becomes simple:
Why not ask?
The danger is not that Americans are uniquely fragile. It is that we have built an economy in which attention functions as a clinical input.
When enough viewers reinterpret fatigue, stiffness, distraction, or sadness through the lens of possibility, clinics feel the pressure. Some of those conversations save lives. Some accelerate overdiagnosis. Many are simply expensive.
Back in the living room, the news resumed. Sofia shifted and sighed.
I unmuted the television and listened to the next commercial break arrive. Another soft-lit couple. Another calm recital of catastrophic risks delivered over birdsong.
I wondered how many viewers would walk into appointments this week carrying a brand name they did not know last month. I wondered how many families with truly rare conditions were still fighting prior authorization while the awareness machine hummed.
We have built a healthcare system where miracles are real—and marketing is louder.
If we want the miracles to feel normal instead of luxurious, the solution is not silence. It is redesign.
Approve platforms once, not from scratch each time.
Pool risk so no insurer has an incentive to stall a cure.